Susquehanna International Group’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-1,800
| Closed | -$7.16K | – | 12934 |
|
|
2022
Q4 | $7.16K | Sell |
1,800
-813
| -31% | -$3.32K | ﹤0.01% | 11991 |
|
|
2022
Q3 | $10K | Sell |
2,613
-6,774
| -72% | -$86K | ﹤0.01% | 12776 |
|
|
2022
Q2 | $125K | Buy |
+9,387
| New | +$62.4K | ﹤0.01% | 11237 |
|
|
2021
Q4 | – | Sell |
-24,907
| Closed | -$768K | – | 13418 |
|
|
2021
Q3 | $768K | Buy |
24,907
+22,827
| +1,097% | +$751K | ﹤0.01% | 8243 |
|
|
2021
Q2 | $68K | Sell |
2,080
-10,107
| -83% | -$347K | ﹤0.01% | 12228 |
|
|
2021
Q1 | $461K | Buy |
12,187
+10,027
| +464% | +$458K | ﹤0.01% | 9671 |
|
|
2020
Q4 | $102K | Buy |
2,160
+667
| +45% | +$28.9K | ﹤0.01% | 10484 |
|
|
2020
Q3 | $48K | Buy |
+1,493
| New | +$58.4K | ﹤0.01% | 10209 |
|
|
2020
Q2 | – | Sell |
-7,147
| Closed | -$234K | – | 10416 |
|
|
2020
Q1 | $234K | Buy |
+7,147
| New | +$328K | ﹤0.01% | 8415 |
|
|
2019
Q2 | – | Sell |
-6,920
| Closed | -$421K | – | 10457 |
|
|
2019
Q1 | $421K | Sell |
6,920
-1,547
| -18% | -$99.4K | ﹤0.01% | 6600 |
|
|
2018
Q4 | $501K | Buy |
8,467
+5,360
| +173% | +$395K | ﹤0.01% | 6024 |
|
|
2018
Q3 | $251K | Sell |
3,107
-13,613
| -81% | -$1.08M | ﹤0.01% | 7816 |
|
|
2018
Q2 | $1.46M | Buy |
16,720
+8,573
| +105% | +$1.5M | ﹤0.01% | 4585 |
|
|
2018
Q1 | $1.58M | Buy |
+8,147
| New | +$1.52M | ﹤0.01% | 4363 |
|
|
2017
Q2 | – | Sell |
-1,787
| Closed | -$126K | – | 9419 |
|
|
2017
Q1 | $126K | Buy |
+1,787
| New | +$104K | ﹤0.01% | 8287 |
|
|
2016
Q2 | – | Sell |
-124
| Closed | -$24K | – | 8838 |
|
|
2016
Q1 | $24K | Sell |
124
-76
| -38% | -$18.3K | ﹤0.01% | 8794 |
|
|
2015
Q4 | $70K | Sell |
200
-46
| -19% | -$18.1K | ﹤0.01% | 9016 |
|
|
2015
Q3 | $129K | Buy |
246
+233
| +1,792% | +$355K | ﹤0.01% | 9015 |
|
|
2015
Q2 | $28K | Sell |
13
-30
| -70% | -$60.1K | ﹤0.01% | 9961 |
|
|
2015
Q1 | $100K | Sell |
43
-31
| -42% | -$64K | ﹤0.01% | 8963 |
|
|
2014
Q4 | $153K | Buy |
74
+3
| +4% | +$5.78K | ﹤0.01% | 8999 |
|
|
2014
Q3 | $141K | Sell |
71
-86
| -55% | -$213K | ﹤0.01% | 8929 |
|
|
2014
Q2 | $557K | Sell |
157
-97
| -38% | -$317K | ﹤0.01% | 7260 |
|
|
2014
Q1 | $949K | Buy |
254
+40
| +19% | +$148K | ﹤0.01% | 5604 |
|
|
2013
Q4 | $699K | Buy |
214
+16
| +8% | +$63.1K | ﹤0.01% | 6137 |
|
|
2013
Q3 | $827K | Buy |
198
+99
| +100% | +$398K | ﹤0.01% | 5621 |
|
|
2013
Q2 | $332K | Buy |
+99
| New | +$377K | ﹤0.01% | 6644 |
|
Other funds holding GYRE
SS
Susquehanna International Group's GYRE Position: Q3 2025 in Review
Susquehanna International Group sold out of Gyre Therapeutics (GYRE) in Q3 2025, closing a stake of 35,912 shares — an estimated $264K sold.
Susquehanna International Group first reported a position in GYRE in Q2 2013 and held it in 25 quarters. The position peaked at $2.36M in Q1 2018. 48 funds tracked by Wall St. Rank hold GYRE as of Q3 2025.
- Susquehanna International Group reported no remaining Gyre Therapeutics position as of Q3 2025 after selling out during the quarter.
- Susquehanna International Group sold 35,912 Gyre Therapeutics shares in Q3 2025, an estimated $264K.
- Susquehanna International Group first reported a position in Gyre Therapeutics in Q2 2013 and held it in 25 quarters.
- Susquehanna International Group's Gyre Therapeutics position peaked at $2.36M in Q1 2018.
- 48 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2025.
Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.